# Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ

> **NCT06761846** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 70 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Esophagogastric Junction Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Sintilimab plus Chemotherapy

## Key facts

- **NCT ID:** NCT06761846
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-17
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761846, "Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06761846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*